System and method for television network in response to input

ABSTRACT

A system and method are provided for collection and of a biologic sample. The method comprises collecting by a user of a testing device a biologic sample for use with the testing device, assigning correlative values as test results, and receiving the test results at a server disposed on a network. Some aspects also include presenting audiovisual messages to the user while the user is waiting for test results to be completed. These audiovisual messages are presented to the user by a mobile application. The audiovisual messages may take several forms, including advertisements and television channels.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.62/434,275, filed on Dec. 14, 2016, entitled SYSTEM AND METHOD FORTELEVISION NETWORK IN RESPONSE TO INPUT, which is incorporated byreference herein in its entirety.

TECHNICAL FIELD

The following disclosure is related to biologic data collection and,more specifically, storage and dissemination of biologic characteristicsdata.

BACKGROUND

When conducting self-diagnostic testing on biologic materials, a testuser may spend significant amounts of time waiting for the results.Therefore, what is needed is a system and method for deliveringaudiovisual messages to a user during the time the user spends waitingfor test results.

SUMMARY

In one aspect thereof, a system and method for collection and testing ofa biologic sample are provided. The method comprises collecting by auser of a testing device a biologic sample for use with the testingdevice, assigning correlative values as test results, and receiving thetest results at a server disposed on a network. Some aspects alsoinclude presenting audiovisual messages to the user while the user iswaiting for test results to be completed. These audiovisual messages arepresented to the user by a mobile application. The audiovisual messagesmay take several forms, including advertisements and televisionchannels.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding, reference is now made to thefollowing description taken in conjunction with the accompanyingDrawings in which:

FIG. 1 illustrates a diagrammatic representation of one embodiment of aimmunoassay test strip;

FIG. 2 illustrates a diagrammatic representation of one embodiment of animmunoassay test wherein an analyte is tested across a plurality of teststrips;

FIG. 3 illustrates a diagrammatic representation of one embodiment of atesting device;

FIG. 4 illustrates a top view of the testing device of FIG. 3;

FIG. 5 illustrates a top view of one embodiment of a testing device;

FIG. 6 illustrates a top view of another embodiment of a testing device;

FIG. 7 illustrates a flowchart of one embodiment of a testing device usemethod;

FIG. 8A illustrates a diagrammatic representation of one embodiment of aprocess for a mobile device application for testing device image captureand image processing, wherein an image alignment indicator is notaligned with the subject of the image;

FIG. 8B illustrates a diagrammatic representation of one embodiment of aprocess for a mobile device application for testing device image captureand image processing, wherein an image alignment indicator is alignedwith the subject of the image;

FIG. 9 illustrates a flowchart of one embodiment of an image analysisprocess using a mobile device;

FIG. 10 illustrates a diagrammatic representation of another embodimentof a process for a mobile device application for testing device imagecapture and image processing, wherein an image alignment indicator isaligned with the subject of the image;

FIG. 11 illustrates one embodiment of a consumer driven biologic anddisease data collection system;

FIG. 12 illustrates one embodiment of a consumer driven biologic anddisease data collection system;

FIG. 13 illustrates an example of a unique biologic ID database table;

FIG. 14 illustrates a flowchart of one embodiment of a biologic datacollection and dissemination process;

FIG. 15 illustrates a perspective view of a system for scanning teststrips;

FIG. 16 illustrates a cross-sectional view of the system of FIG. 15;

FIG. 17 illustrates one embodiment of a vertical flow immunoassaydevice;

FIG. 18 illustrates a cross-sectional view of one embodiment of thevertical immunoassay device of FIG. 17;

FIG. 19 illustrates a color gradient chart;

FIG. 20 illustrates a normalized past tests results rating chart;

FIG. 21 illustrates a mobile device displaying on a screen a mobileapplication variable test functionality; and

FIG. 22 illustrates the mobile device of FIG. 21, wherein a housing of atesting device also includes thereon test function indicators;

FIG. 23 illustrates a mobile device displaying audiovisual instructionsfor performing a self-diagnostic test;

FIG. 24 illustrates a process for using a mobile device camera tocapture an image of a scan-able code to determine which set ofinstructions is correct for a self-diagnostic test;

FIG. 25 illustrates a process for entering a product code into a mobiledevice on a mobile application for the purpose of obtaining instructionsfor a self-diagnostic test;

FIG. 26 illustrates an acknowledgement screen on a mobile applicationfor a user to acknowledge understanding self-diagnostic testinstructions;

FIG. 27 illustrates a flowchart depicting a process for presentingself-diagnostic test instructions to a user;

FIG. 28 illustrates a flowchart for generating test results with aremote server and database from an image communicated by a mobileapplication on a mobile device;

FIG. 29 illustrates a mobile device displaying audiovisual messages to aself-diagnostic test user; and

FIG. 30 illustrates a flowchart depicting a process for presentingaudiovisual messages to a self-diagnostic test user.

DETAILED DESCRIPTION

Referring now to the drawings, wherein like reference numbers are usedherein to designate like elements throughout, the various views andembodiments of an arbovirus indicative birth defect risk test areillustrated and described, and other possible embodiments are described.The figures are not necessarily drawn to scale, and in some instancesthe drawings have been exaggerated and/or simplified in places forillustrative purposes only. One of ordinary skill in the art willappreciate the many possible applications and variations based on thefollowing examples of possible embodiments.

Referring now to FIG. 1, there is illustrated one embodiment of animmunoassay test strip 100. The test strip 100 is typically housed in atesting device configured to collect a biologic analyte 106 from a userand to direct to the biologic analyte 106 onto the testing strip 100.However, it will be understood that the biologic may be applied onto astrip 100 without the strip 100 needing to be within a testing device.The test strip 100 includes a backing 102. The test strip 100 is made upof multiple sections disposed on the backing 102. A sample pad 104 isdisposed on one end of the strip 100, for collecting the biologicanalyte 106. The biologic analyte 106 may be any biologic needed for usein the immunoassay, such as urine, blood, saliva, stool, sweat, or otherbiologics to be used as an analyte. Various methods may be used toacquire the needed biologic, and such may be provided to the userpackaged with the test, such as swabs, vials, containers, dilutants andother solutions, or any other equipment required. In the case of a bloodanalyte, a few drops of blood may be obtained from a finger stick usinga finger prick device. Such a blood analyte may be blood mixed with anadequate amount of buffered solution to create the sample analyte 106 ora blood sample that is not diluted or otherwise manipulated, in whichcase the blood only is the analyte 106.

The biologic analyte 106, after coming into contact with the sample pad104, begins to migrate across the strip 100 by capillary action, cominginto contact with other sections of the strip 100. A particle conjugatepad 108 is disposed between the sample pad 104 and a test line 110. Theconjugate pad 108 may contain various reagents associated with aparticular antigen, such as a virus, allergen, or bacteria, the reagentsbeing items such antibodies, enzymes, or other reagents needed todiagnose the particular condition. The reagent in the conjugate pad 108may be conjugated with particles of materials such as colloid gold orcolored latex beads. As the analyte 106 migrates through the conjugatepad 108, antibodies present in the sample analyte 106 complex with thereagents in the conjugate pad 108, thereby creating an immune complexthat will migrate to the test zone or test line 110.

The test line 110 (T) may be precoated with the relevant antigen inquestion, i.e., a virus, allergen, or bacteria, for the detection ofantibodies associated with the particular antigen. The immune complexcreated when the analyte 106 passes through the conjugate pad 108 iscaptured onto the antigen contained on the test line 110. This maycreate a qualitative response on the strip where the test line 110 islocated, such as a colored response. In some embodiments, the test line110 may not be a line, but may be other shapes or symbols, such as aplus sign. If no antigen-anti-antigen complexes are present in theanalyte, no reaction occurs in the test line 110 and a qualitativeresponse will not occur.

After passing through the test line 110, the analyte migrates furtheralong the strip to reach a control line 112, where excessanti-antibody-colloidal gold or latex conjugates get bound. Aqualitative response may be shown at the control line 112, indicatingthat the sample has adequately migrated across the testing membrane orsubstrate as intended. It will be understood that the control line 112is not necessarily needed to perform the test, and may be eliminatedentirely, but the control line 112 does provide a comparative examplefor a user reading the test. For example, the control line 112, inembodiments where a colored qualitative response is provided, may appearas an overly saturated color, such as a dark or bright saturated red,once the sample reaches the control line 112. This saturated color maybe used as a comparison against the qualitative response shown on thetest line 110. For example, if the qualitative response shown on thetest line 110 is a much lighter red than that on the test line 110, itmay be that very little reaction occurred at the test line. Of course,if no response is shown at all at the test line 110, no reaction hasoccurred. If the qualitative response at the test line 110 is of asimilar saturation to the control line 112, a strong reaction isindicated.

The strip 100 may not be a continuous substrate. Rather, the varioussections of the strip 100 may be separate from each other, but alladhered to the backing 102. As shown in FIG. 1, the sample pad 104 andthe conjugate pad 108 are separate structures from each other. The testline 100 or zone and the control line 112 or zone are both disposed aspart of a nitrocellulose membrane strip 114. The nitrocellulose membranestrip 114 is also adhered to the backing 102, but separate from thesample pad 104 and the conjugate pad 106. As shown in FIG. 1, the end ofthe sample pad 104 adjacent to the conjugate pad 106 may overlap theconjugate pad 106, with that end of the sample pad 106 lying over theadjacent end of the conjugate pad 106. Similarly, the end of theconjugate pad adjacent to the nitrocellulose membrane strip 114 may lieover the end of the nitrocellulose membrane adjacent to the conjugatepad. This allows for the analyte 106 to be more easily deposited ontoeach section of the strip 100 as it migrates across the strip 100. Afterthe analyte 106 migrates across the nitrocellulose membrane strip 114,and thus across the test line 110 and the control line 112, the analyte106 comes into contact with a wick 116 for absorption and collection ofthe analyte 106. The end of the wick 116 adjacent to the nitrocellulosemembrane strip 114 may lie over that adjacent end of the nitrocellulosemembrane strip 114, as shown in FIG. 1.

Several Flow Immune Assays have been directed toward identifyingproteins, molecules of interest, and even immunoglobulins IgG, IgA, andIgM. IgE is an antibody (immunoglobulin E) that is normally present inthe blood freely circulating until it moves into the tissue where it isbound to mast cells through the receptor FcERI (F-C-epsilon-R-one)otherwise known as the high affinity IgE receptor. There is a smallamount of IgE bound to IgE receptors (high and low affinity receptors)on basophils, eosinophils, and other cells in the blood and tissues.

Many assay systems are geared toward the detection of infectiousproteins. All of the aforementioned tests use a non-humanantibody—usually IgG type—e.g., goat IgG antibody directed against aprotein of interest to detect the protein of interest from the sample(blood, urine, saliva, sweat, etc.). This antibody complexes withprotein of interest and forms a complex that travels across the membraneuntil it reaches the test zone. In the test zone there is an IgG typeantibody directed against IgG from that species of animal. As furtherdescribed herein, the present detecting apparatus and method use human(patient/consumer-derived) antibodies from the sample and the test zonethat contains a humanized antibody directed against the protein ofinterest that is preconjugated to a detecting substance that results ina visual change.

Summary of Target Antigen:

-   -   The target antigens may be proteins, glycoproteins, lipoproteins        or other molecular substances capable of eliciting an immune        reaction and/or being bound by human specific IgE (sIgE).

Immune Assay to Detect Specific IgE:

-   -   In the detecting apparatus and method of using the same, the        antigens are proteins conjugated to a noble metal, for example,        gold, or latex conjugated to antigen in the test zone, for the        purpose of detecting the presence of specific IgE (e.g.,        anti-peanut IgE in a blood sample from a finger prick). For        example, an IgG class antibody (IgG1, IgG2, IgG3, or IgG4) or        fragments of those classes of antibodies (fab fragments) whose        origin may be any animal species (goat, rat, human, etc.)        capable of detecting human IgE (anti-IgE IgG)—a suitable        commercially available humanized antibody, such as omaluzimab        may be used—may be used to form immune complexes of        IgG-anti-IgE-sIgE that will migrate to the test zone having        selected specific IgE that can bind to the conjugated antigen.

Immune Assay to Detect Total IgE (not Concerned about Specific IgE):

-   -   Another embodiment includes using an IgG class antibody (IgG1,        IgG2, IgG3, or IgG4) or fragments of those classes of antibodies        (fab fragments) whose origin may be any animal species (goat,        rat, human, etc.) capable of detecting human IgE (anti-IgE        IgG)—a suitable commercially available humanized antibody that        is preconjugated to a detecting molecule that results in a color        change when bound to IgE as the target antigen in the test zone.

Referring now to FIG. 2, there is illustrated one embodiment of animmunoassay test 200 wherein an analyte 202 is tested across a pluralityof test strips 204. The plurality of test strips 204 may each beconfigured for testing for a particular antigen. For instance, one stripmay be for testing for the presence of streptococcal bacteria (strepthroat), one strip may be for testing for a peanut allergy, one stripmay be for testing for the Zika virus, etc. Additionally, each strip mayalso test for multiple antigens. For example, as shown in FIG. 2,multiple testing panels or lines maybe be incorporated. Each line may befor a particular antigen. As shown in FIG. 2, multiple test lines 206,208, and 208 may be disposed along the plurality of strips 204. A striptesting for allergens may have a panel for testing for peanut allergiesshown at test line 206 (CH1), for cat allergies shown at test line 208(CH2), or grass allergies shown at test line 210 (CH3).

Other examples of configurations for the testing panels can be, but arenot limited to: 1) Food 5: Peanut, milk, soy, wheat, egg; 2) Nut andseed panel: almond, cashew, hazelnut, peanut, pecan, walnut, sesameseed, sunflower seed; 3) seafood: crab, lobster, shrimp, salmon, tuna;4) Pets: cat, dog; 5) Indoor allergens: dust mites, mold mix(alternaria, aspergillus, penicillium, cladosporium), cat, dog; and 6)seasonal allergens: grass (Bermuda, bahia, Johnson, rye, timothy), trees(oak, elm, cedar, mesquite, pine, etc.), weeds (pigweed, ragweed, sage,Russian thistle).

With respect to other non-allergen antigens, the panels may be fortesting for strep, Zika, flu, anthrax, cold viruses, cancer, HPV, Lymedisease, mononucleosis (mono), and other illnesses, and/or otherconditions such as pregnancy (hCG detection) and disease risks. Someembodiments may allow for the testing of various arboviruses(arthropod-borne viruses). Arboviruses are viruses that are transmittedby arthropods, with mosquitoes being a common vector for the virus.Vectors are organisms that transfer the virus from a host that carriesthe virus. Thus, in the case of mosquitoes, a mosquito that feeds on ahost that is infected with a virus may infect others when that mosquitoagain feeds on an uninfected host. Well-known arboviruses include Denguevirus, Japanese encephalitis virus, Rift Valley fever virus, West Nilevirus, yellow fever virus, chikungunya, and Zika virus. Urine, blood,and saliva and other biologics may be used for arboviruses testing.

Certain antigens or medical conditions may be logically paired together.For instance, a testing device may include both a strip for detection ofpregnancy and a strip for the detection of the zika virus, as the Zikavirus has been known to cause birth defects in infants born to pregnantwomen that are infected with Zika. Thus, combining these two tests intoa single testing device or kit would alert a woman to a potential Zikainfection proximate in time to the time she also discovers she ispregnant, allowing the woman to seek medical attention immediately. Thisis a substantial improvement over past Zika testing, where a woman maybe required to wait weeks before results are returned from a lab afterhaving the biologic collected by her physician. In many cases, this maylead to a woman having passed a state-mandated cutoff point forabortions, such as 24 weeks in some states. Combining a Zika test with apregnancy test and physically linking the two tests, and thus allowingfor a woman to determine a Zika risk at the time of taking a pregnancytest, in which a pregnancy test may be taken as soon as six days afterconception, allows for that woman to take action much sooner than thestate mandated cutoff and waiting for lab results would allow.

Various testing devices that include the test strip 100 or strips may beused, such as a slide that supports the test strip 100, a cassette baseddiagnostic test, a dipstick, or combinations thereof. The test resultsin various embodiments may be in the form of a visual qualitativereading test, a visual semiquantitative format, a reader quantitativeassay format, and/or combinations thereof. Additionally, an electronicimplementation may be used where the result is displayed digitally on ascreen disposed within the apparatus, and visible to the user.

The apparatus and method of detection may be a “one-step” approach fromsample to reading without sample dilution or other sample manipulation.The sample may be diluted or endure other sample manipulation, forexample the blood sample is diluted with a buffer.

Referring now to FIG. 3, there is illustrated a diagrammaticrepresentation of one embodiment of a testing device 300. The testingdevice 300 includes a housing 302 that forms the body of the testingdevice. The housing 302 may be made of plastic, metal, or any materialdurable enough for shipping and subsequent handling by a user. Thehousing 302 may be hollow so that a plurality of test strips 304 may behoused within and so that a biologic may be deposited within the housing302. The testing device 300 may further have a plurality of windows 306,each window being associated with one of the plurality of test strips304, and allowing for a user to view at least the section of thenitrocellulose membrane strip 114 where the test line 110 and controlline 112 are located. The plurality of windows 306 may be open, orcovered with plastic, glass, or other materials that allow for viewingthe plurality of strips 304. A sample well 308 may be disposed on asurface of the housing 302 to allow a user to deposit a biologic intothe housing 302. The sample well 308 would be disposed over or near thesample pad 104 of the test strip or strips 100. In the embodiment shownin FIG. 3, a single sample well 308 is included for collection of asingle type of biologic for testing, with each of the plurality ofstrips 304 being suited for testing for antigens using that particularbiologic sample type. For example, if the testing device 300 is acombined pregnancy and Zika test, having both a pregnancy strip and aZika strip, a urine sample may be deposited into the sample well 308,causing the urine sample to come into contact with the sample pad 104 onboth the pregnancy strip and the Zika strip. It will be understood thatboth of these tests may also be performed with a blood sample.

The testing device 300 may also have disposed on the surface of thehousing a crosshair symbol 310, used as an alignment target. This symbolmay be a graphic printed or adhered to the testing device 300. Thecrosshair symbol 310 is used to align the testing device 300 for thetaking of an image of the testing device 300 using a camera on a mobiledevice, for use in a mobile device application described herein. Inother embodiments, the crosshair symbol 310 may be other types ofsymbols, such as a simple shape (circle, square, etc.), other images(such as a medical cross symbol, an arrow, etc.), or any other type ofimage.

Referring now to FIG. 4, there is illustrated a top view of the testingdevice 300. There is again shown the housing 302, the plurality of teststrips 304, the plurality of windows 306, the sample well 308, and thecrosshair symbol 310.

Referring now to FIG. 5, there is illustrated a top view of oneembodiment of a testing device 500. The testing device 500 includes ahousing 502 having a plurality of test strips 504 within the housing 502and a plurality of windows 506 for display of the plurality of strips504. The housing 502 also includes a plurality of sample wells 508disposed on one side of the testing device 500. Each of the plurality ofsample wells 508 is associated with one of the plurality of test strips504 and each of the plurality of sample wells 508 may be disposed overone of the sample pads 104 on the associated one of the plurality oftest strips 504. This allows for a biologic to be deposited into each ofthe plurality of sample wells 508, with each well 508 serving totransfer the biologic to the test strip underneath the sample well. Thetesting device 500 further includes a crosshair 510. The crosshairsymbol 510 is used to align the testing device 500 for the taking of animage of the testing device 500 using a camera on a mobile device, foruse in a mobile device application described herein.

Referring now to FIG. 6, there is illustrated a top view of anotherembodiment of a testing device 600. The testing device 600 includes ahousing 602 having a plurality of test strips 604 within the housing 602and a plurality of windows 606 for display of the plurality of strips604. The housing 602 also includes a plurality of sample wells 608. Inthis embodiment, the sample wells are located on different ends of thehousing 602. In the case of a two test strip device, the sample wells608 are disposed on opposite ends of the testing device 600. The strips604 would be arranged within the housing in such a way as to allow thesample pad 104 on each of the strip to be disposed underneath one of thesample wells 608. This is useful for testing devices that requiredifferent biological samples. For example, if the testing device 600required a urine sample for one strip and a blood sample for the otherstrip, having the wells 608 disposed on opposite sides of the testingdevice would reduce the likelihood that a urine sample, for instance,might be inadvertently deposited into the well designated for the bloodsample. In embodiments where there are more than two strips, and morethan two wells, the well positions may alternate between the two sidesof the testing device. For instance, a first well for a first stripmight be disposed on the left side of the testing device, a second wellfor a second strip might be disposed on the right side of the testingdevice, a third well for a third strip might be disposed on the leftside of the testing device, a fourth well for a fourth strip might bedisposed on the right side of the testing device, and so on. The testingdevice 600 further includes a crosshair 610. The crosshair symbol 610 isused to align the testing device 600 for the taking of an image of thetesting device 600 using a camera on a mobile device, for use in amobile device application described herein.

The diagnostic test can, for example, be produced in a various formatsfor different users, such as, but not limited to, consumer/in-home usewhere the test is purchased through retail channels which will allowindividuals to get an immediate, cost-effective test result that canlead to specific avoidance and treatment through follow-up with amedical professional.

The diagnostic test can be provided to and used by hospitals and clinicsto provide rapid, on-site test results that are required to prescribecertain medications, such as omaluzimab, by their FDA labels.

This diagnostic assay can be modified to detect the presence of specificIgE in pets.

It is also noted that housing 602 is designed such that both strips 604are disposed in physical proximity thereto and in the same actualhousing. In this manner, both sets are linked physically to each othersuch that they cannot be separated and can be associated with a singleindividual and the actual test cannot be separated. As such, when apatient applies the specimens to the two areas 608 and the test resultsare exhibited, there is a high probability that two tests were performedat the same time associated with the same patient. Additionally, andelectronic chip (not shown) can be embedded within the housing 602 suchthat the housing 602 can be registered to a specific patient andassociated with the medical records of that patient.

Referring now to FIG. 7, there is illustrated a flowchart of oneembodiment of a testing device use method 700. The method 700 begins atstep 702 where a biologic is collected in a sample well or wells of atesting device. The biologic collected may be a non-diluted ornon-manipulated biologic, such as blood, urine, or saliva from the userof the test. Diluted or manipulated biologics may be used instead, asrequired by the specific test. For example, if a viral test requires thebiologic to be added to a solution, the biologic could be added to asolution that has previously been placed in a sterilized vial providedwith the testing device. After the required amount of time has passed,the solution containing the biologic could be deposited into the well orwells. At step 704, the biologic contacts a sample pad disposed on astrip or strips within the testing device. At step 706, the biologicmigrates along the strip or strips to come into contact with a conjugatepad containing antibodies. Antibodies present in the biologic willcomplex with the antibodies in the conjugate pad to create an immunecomplex. At step 708, the biologic migrates into a test zone of thestrip or strips, coming into contact with an antigen. The antibodies inthe conjugate pad serve to provide a means of detection, such as acolored response, if the immune complex binds with the antigen presentin the test zone of the strip. At decision block 710, binding of theantibodies with the antigen may or may not occur depending on ifantibodies associated with the antigen are present in the biologic ornot. If a binding between the antibodies and the antigen does not occurthe process moves to step 712 where no qualitative response is producedon the test line. If a binding does occur, at step 714 a qualitativeresponse is produced on the test line. Whether a binding occurs or not,and whether a qualitative response is produced or not, the process movesto step 716 where the biologic migrates into a control zone of the stripor strips where excess conjugates get bound and produces a qualitativecontrol zone reaction indicating that the sample has adequately migratedacross the testing zone.

It will be understood by one skilled in the art that the antibodies andantigens applied to the testing strip may be altered depending on thetype of condition being tested. For example, in the case of testing formedical conditions that do not involve an illness or infection, likepregnancy, and thus the sample biologic does not contain antibodiesassociated with the condition, antibodies that react to markers beingtested for may be applied to the testing strip instead of an antigen.For instance, pregnancy test requires testing for the presence of hCG.Since hCG is a hormone and not an antibody produced in response to aninfection, the testing strip may have antibodies that will react to thepresence of hCG applied to the testing zone or line of the testingstrip, as well as to the conjugate pad. Similarly, some tests mightrequire antibodies be applied to the testing strip to detect antigenspresent in the sample, rather than antibodies.

Referring now to FIGS. 8A and 8B, there is illustrated a diagrammaticview of one embodiment of a process 800 for a mobile device applicationfor testing device image capture and image processing. The mobile deviceapplication allows for an image of a testing device, such as testingdevice 300, to be captured using a camera installed on a mobile device802 having a screen 804. While the mobile device 802 displays on thescreen 804 the scene captured by the camera, the mobile deviceapplication also displays a graphic on the screen 804 in the form of aboxed outline 806, the size of the outline 806 corresponding to the sizeof the testing device 300. Also displayed on the screen of the mobiledevice 802 within or near the outline is a crosshair graphic 808. A userof the mobile device 802 attempts to align the outline 806 with theborders of the testing device 300 and also attempts to align thecrosshair graphic 808 with the crosshair 310 on the testing device 300.While alignment has not yet been achieved, a misalignment warning 810may appear on the screen of the mobile device 802, indicating to theuser that alignment has not yet been achieved. Such is shown in FIG. 8A.

In FIG. 8B, there is shown the result of a successful alignment of theoutline 806 with the testing device 300 and successful alignment of thecrosshair graphic 808 with the crosshair 310 on the testing device 300.As shown in FIG. 8B, once aligned, a success indicator 812 may appear,such as a check mark or other positive status symbol, on the alignedimage. Successful alignment causes the camera on the mobile device 802to capture the current image of the testing device 300. Other checks mayoccur, including ensuring that the image is focused before the image issaved. This image is then processed to determine a result based on theseverity of the reaction occurring on the test strip. The mobile deviceapplication performs an analysis of the test line captured in the image,counting the number of colored pixels, as well as determining theintensity of the color. The mobile device may then compare this numberand color intensity to that in the control line, providing amathematical evaluation of the test line. Utilizing unique wavelengthsof light for illumination in conjunction with either CMOS or CCDdetection technology, a signal rich image is produced of the test linesto detect the colloid gold or latex particles. This provides anadvantage because a user simply looking at the two lines may not knowwhat the test line indicates, such as when the colored line does appearson the strip, but it is a faded line, rather than a dark line. Based onthis analysis, the mobile device application may provide a resultsindicator 814.

The results indicator 814 may be a qualitative result or a quantitativeresult. For example, and as shown in FIG. 8B, a qualitative result forthe results indicator 814 may indicate, in the case of a testing devicefor testing pregnancy as well as an infection, a plus sign next to aline reading “pregnant:” and a plus sign next to a line reading“infection:” to indicate that the user is both pregnant and infectedwith the bacteria or virus being tested, such as the Zika virus. For aquantitative result, the results might provide a numeric rating. Forinstance, a rating system between 1-100 may be used. If the resultsprovide a low rating to the user, such as a rating of 10, this indicatesa low risk of infection, although medical attention may be sought by theuser anyway. For example, if the user is pregnant, and also receives a10 rating for Zika, this may indicate that Zika was detected in lowamounts. However, the user may still seek medical attention or furthertesting from her doctor because Zika has been known to cause birthdefects. If the rating is a high rating, such as 95, this indicates thatan infection has most likely occurred and medical attention should besought immediately.

This same quantitative rating system may be applied to any test (viralinfections, bacterial infections, pregnancy, and other healthconditions), as the quantitative test can be performed using thesoftware described herein to accurately test bound antibodyconcentrations on the test strip. In some embodiments, a combinedqualitative and quantitative result may be presented, such as both arating and a plus or minus sign being presented, or other types ofquantitative and qualitative indications. Additionally, variouscombinations of tests may be provided for in the testing device, such aspregnancy/Zika, preganancy/flu, pregnancy/strep/Zika, etc.

Referring now to FIG. 9, there is illustrated a flowchart of oneembodiment of an image analysis process 900 using a mobile device. Atstep 902 a mobile device application is launched. At step 904 a cameraon the mobile device is activated and a crosshair indicator and atesting device outline appear on the mobile device screen. At step 906the crosshair indicator presented on the screen of the mobile device isaligned with a crosshair icon on the testing device and the deviceoutline presented on the screen of the mobile device is aligned with theborders of a testing device. At step 908, an indicator of successfulalignment is presented on the screen and an image of the testing deviceis taken by the mobile device camera. At step 910, the mobile deviceapplication processes the image of the testing device to determine testline strength by counting the number of colored pixels contained in thetest line. At step 912, the mobile device application correlates lineintensity with analyte concentrations to further determine test linestrength. At step 914, the mobile device application presents the testresults based on pixel count and line intensity, providing either aqualitative or quantitative result.

In some embodiments, the number of pixels indicating bound antibodies onthe strip may be measured against that in the control line to compareline intensity between the two lines, with the control line acting as anexample of a strong reaction, indicating a strong infection, anddetermining how close the test line intensity is to the control line.This would lead to a logical quantitative result. For instance, if thetest line is determined to have a pixel count and line intensity that is25% of the pixel count and line intensity of the control line, a ratingof 25 may be given. If a qualitative result is to be provided, a ratingof 25 may give a qualitative result that is negative, or it could bepositive depending on the type of condition being tested and knownactual infection results where a rating of 25 occurred for thatcondition.

In some embodiments, the test line may not be compared with the controlline to determine a result. Rather, the mobile device application mayhave access to a database having data on numerous past tests for thesame condition. This data may instead be used as the control. Thisallows the application on the mobile device to retrieve data on pasttests and compare the test line data of the current test to past tests.Overall data for past tests may be provided and compared against, suchas providing an average or a curve of past tests, or individual testsrated as having accurate results may be compared against.

In addition to a status result of an infection or other medicalcondition being provided to the user, other indicators of health mayalso be tested and results thereon provided. This provides for potentialearly identification of pregnancy and risk of morbidity, allowing formedical attention to be sought much more quickly. Indicators of healthmay be detected from biologics, such as urine and blood. Urine, forexample, allows for the detection of glucose levels, proteins, bacteria,and infectious markers. In the case of glucose, glucose is usually notfound in urine, but, if it is, that is an indicator of extremely highlevels of glucose in the body, where the kidneys release excess glucoseinto urine. This is often a sign of diabetes. Protein in the urine mayindicate a malfunctioning of the kidneys, which could be the result ofhigh blood pressure. Similarly, if blood is detected in urine, it couldbe a sign of a problem with the kidneys or the bladder. Blood, forexample, allows for the detection of glucose, inflammation, hormones,genetic defect risks, and metabolic endocrine disorders.

Referring now to FIG. 10, there is illustrated another embodiment of asuccessful alignment of the outline 806 with the testing device 300 andsuccessful alignment of the crosshair graphic 808 with the crosshair 310on the testing device 300, wherein quantitative results for health riskindicators are provided. In this embodiment, the results indicator 814provides a qualitative result for pregnancy, and quantitative resultsfor other health risk indicators. In the embodiment shown in FIG. 10,the health risk indicators being tested are markers for blood pressureand for glucose levels. For blood pressure, this is a test for markersin the blood that can be associated with high blood pressure. Thesecould be test for such things as low levels of vitamin D and the such.Studies have shown that patients suffering from essential hypertensionwill be under oxidative stress and Malondialdehyde (MDA) is theprincipal and most studied product of polyunsaturated fatty acidpre-oxidation. This can show an indirect correlation with anti-oxidants,particularly with superoxide dismutases (SODs) (r=0.573) and catalase(r=0.633) representative anti-oxidant are involved in reducing thestress of a patient's biological system during hypertension. Anothermarker for hypertension is buildup of uric acid, where in uric acid is amarker for xanthine oxidase-associated oxidants and that the lattercould be driving the hypertensive response. Additional markers arecortisol, a hormone. The test strips 604 can test for the differentbiological markers.

The results indicator 814 provides numeric ratings, in this case, 1-100,with the blood pressure rating being 88 and the glucose rating being 95.This indicates that both blood pressure and glucose are extremely high.Due to this, an additional alert indicator 1002 is presented to the useron the screen of the mobile device, alerting the user to seek medicalattention immediately. This is to ensure that the health of both thepregnant woman and the fetus can be checked as close to the time ofpregnancy detection as possible and medical attention received ifneeded.

Referring now to FIG. 11, there is provided a flowchart of oneembodiment of a pregnancy disease risk assessment process 1100. Theprocess 1100 begins at step 1102 where a biologic is collected anddeposited in a testing device for testing of the biologic. At step 1104,the biologic is processed by the testing device for detection ofpregnancy and various other medical conditions. These medical conditionsmay be high blood pressure, diabetes, bacterial or viral infections,inflammation, an increase in hormone levels, genetic disease markers,and/or metabolic disorders. At step 1106, a mobile device is used tocapture an image of the testing device after testing is complete. Insome embodiments, test results may be immediate. In other embodiments,and depending on the medical conditions being tested, the test may takea certain amount of time to complete. In this case, the user of the testwould be alerted to this fact in instructions provided with the testingdevice. Additionally, a visual indicator on the testing device may alertthe user that a test is now complete. At step 1108, the mobile deviceprovides a rating for each medical condition being tested, such as thatdescribed with respect to FIG. 10 herein.

At decision block 1110, it is determined whether the ratings for eachcondition exceed a certain threshold for that condition. If not, theprocess 1100 moves to step 1112, where an indication is presented to theuser via the mobile device screen that medical attention is notcurrently advised or necessary. If at step 1110 it is determined that atleast one of the medical conditions being tested rises above a certainthreshold, the process 1100 moves to step 1114 where a warning ispresented to the user via the mobile device screen that medicalattention is advised. The thresholds for medical conditions may nottrigger a warning even if a rating exceeds a threshold, if, in the eventof multiple tests being performed, the combined test results do notwarrant immediate medical attention. For example, if a user is testingfor a cold virus, blood pressure, and glucose, and only the cold virusrating is above the threshold, there may not be a warning provided tothe user. Additionally, ratings may be weighted or aggregated based onthe medical conditions being tested. For example, if blood pressure,inflammation, and glucose are being tested for, and they all are givenonly moderate ratings that do not rise above the threshold for anycondition individually, an warning to seek medical attention may stillbe provided due to the combination of conditions taken together.

Referring now to FIG. 12, there is illustrated one embodiment of aconsumer driven biologic and disease data collection system 1200. Datacollected from users performing the tests disclosed herein effectivelycan provide a wealth of information. As tests are performed data may bepassed by a plurality of mobile devices 1202 being used by usersperforming tests to a database 1204, the database being at a remoteserver 1206, over a network 1208. The user is sourcing a biologic fromuser's own body. This is done at home, not in a lab, hospital, orclinic. Each particular test would expect a certain type of biologic tobe provided. For instance, for a pregnancy test, a urine sample isprovided and tested for pregnancy markers. For a stool test, the stoolmight be dissolved in a vial with a solution provided with the testingdevice/kit, and tested for various disease or infectious markers. Dataand results from the tests may be stored on the database 1204 at theremote server 1206. As described herein, this data may be used as acontrol for testing analysis for users of the plurality of mobiledevices 1202. This data may also be used to provide data sets forbiologics to a medical organization 1210. The medical organization 1210may be doctor's offices, researchers, hospitals, testing labs, and otherindividuals or organizations that have an interest in the health andanalysis of users taking the test and of their biologic samples. In thisway, data can be gathered from a variety of biologics tested for avariety of different medical conditions and characteristics.

Referring now to FIG. 13, there is illustrated an example of a uniquebiologic ID database table 1300. The table 1300 is illustrative of thetype of data stored in association with data for a biologic transmittedby the plurality of mobile devices 1202 for storage on the database1204. A biologic ID header 1302 is provided that shows that the biologicsample has been given a unique ID. All data concerning the biologic maybe stored in association with the unique biologic ID. The table 1300also includes a biologic type entry 1304. This designates what type ofbiologic that the biologic associated with the unique ID is, such asblood, urine, stool, saliva, sweat, or other biologics. The table 1300also provides a plurality of test ratings 1304, for various testsperformed on the biologic. In the example shown in FIG. 13, a bloodbiologic is provided having an assigned ID of 2402, and having beentesting for pregnancy markers, the Zika virus, and for glucose levels.The rating for pregnancy was a 99 rating, the rating for a Zikainfection was a 75, and the rating for glucose levels was a 10. Thiswould indicate that the test subject has an extremely high likelihood ofboth a pregnancy and a Zika infection, which would have resulted in awarning to seek medical attention at the conclusion of the tests. Otherinformation may also be stored in the database in relation to thebiologic, including other condition ratings, time and date each test wasperformed, user information such as ethnicity, gender, and age, andstatus indicators such as whether a test subject visited a physician asa result of the tests. The database 1204 thus provides the test subjectwith a growing collection of information that may be accessed by thetest subject. This allows the test subject to present the test resultsto her physician for medical attention or additional testing, and allowsfor others who may access the database, such as disease researchers, tohave access to data on various biologic samples and their markers.

Referring now to FIG. 14, there is illustrated a flowchart of oneembodiment of a biologic data collection and dissemination process 1400.The process 1400 begins at step 1402 where a user of a testing devicecollects a biologic sample for use in a test or a series of tests. Atstep 1404, the test or series of tests are performed on the biologicsample. At step 1406, a mobile device application checks the biologicsample the testing device result to determine a quantitative result ofthe test to provide a correlative value for the condition being testedin the biologic sample. At step 1408, the test results and correlativevalues, or multiple values if multiple tests on the biologic sample wereconducted, are transmitted to the remote server 1206. At step 1410, thebiologic sample is given a unique identification number in the database1204. At step 1412, the test results and correlative value or values arestored in the database 1204 in association with the uniqueidentification number given to the biologic sample collected and inassociation with the particular tests performed. This way, theparticular biologic sample may have various characteristics stored andretrieved in association with the biologic sample, and the test resultsmay also be retrieved when data on a particular test is needed on across-section of users.

At step 1414, the results are provided to the user on the user's mobiledevice. At step 1416, the results are provided to the user's healthcareprovider. The healthcare provider may receive the test results due to avisit from the user, the user bringing the results of the test with heron her mobile device, or the healthcare provider may receive the resultsfrom the database 1204 if the healthcare provider has permission toaccess the database 1204, or if access is granted in anticipation of theuser's appointment with the healthcare provider. At step 1418, the testresults are also provided to other healthcare industry individuals andorganizations, including medical researchers, hospitals, and others.

Referring now to FIG. 15, there is illustrated a perspective view of asystem for scanning test strips. The housing 604, as describedhereinabove with respect to FIG. 6, is illustrated as being disposedwithin a slot 1502 in a test housing 1504. The test housing 1504 isconnected through a line 1506 to a PC 1508. When the housing 604containing the test strips 604 after being subjected to the biologics isinserted within the slot 1502, the test housing 1504 will scan the teststrips 604 and analyze the results with the PC 1508. The PC 1508 willrun some type of algorithm that can analyze the results of both of thetest strips 604. There can be provided to indicators 1510 and 1512 onthe surface of the test housing 1504, one being, for example, a readyLED and one being a green LED. The PC 1508, after analyzing results, canthen provide a warning indicator such as lighting up the green LED for apositive indication of pregnancy and the red LED for indicating thatthere is some issue. As an example, suppose that the second test striptested for the Zika virus. If so, a warning would be appropriate tooutput and activate the red LED. There could be any other type ofindicator associated with the second test at 604 that, in a combinationwith the test results of the first test strip, i.e. for testing for thepresence of a pregnancy state, testing for such things as diabetes, etc.Further, although only two test strips 604 are illustrated, there couldbe multiple test strips testing for many different biological issuesthat may be present in an individual. In this embodiment, by insertingthe housing 602 into the test housing 1504 and allowing the PC 1508 toanalyze the results, the indicators associated with the test strips canbe analyzed with the assumption that all of the test return results wereassociated with an individual and in proximate time to each other. Thatmeans that the individual patient applied biological specimens, such asurine, blood, etc., to the appropriate test strips and, since these wereall contained within the same test strip housing 602, this provides anindication that they are associated with a single patient. Further, thetest performed will typically be a test that will provide a veryshort-term response. Thus, the specimens can be applied to the teststrips 604 in the test strip housing 602 and then inserted within theslot 1502 for testing by the PC 1508.

Referring now to FIG. 16, there is illustrated a cross-section of thetest housing 1504. It can be seen that the test strip housing 1602 ispassed in slot 1502 past the camera 1602. The camera 1602 is operable toscan a small cross-section of the test strips 604 on the surface thereofas the test strip housing 602 passes thereby. Of course, there couldalso be a much larger camera provided for taking an entire image of thetest strips 604 after being inserted within the test housing 1504. Thecamera 1602 is connected via a wire 1604 two in electronics package 1606to process the information and send it to the PC 1508. The electronicspackage 1606 will also drive the indicators 1510 and 1512.

Referring now to FIG. 17, there is illustrated one embodiment of avertical flow immunoassay device 1700. It will be understood thattesting device 300 and other embodiments herein illustrate a lateralflow immunoassay device. However, other types of immunoassay devices maybe used. For example, vertical flow immunoassay devices may be used, atwo-sided flow through assay, or even a sandwich ELISA test may be run.

The testing device 1700 includes a housing 1702 that forms the body ofthe testing device. The housing 1702 may be made of plastic, metal, orany material durable enough for shipping and subsequent handling by auser. The housing 1702 may be hollow so that a plurality of immunoassaytest pads 1704 may be housed within and so that a biologic may bedeposited within the housing 1702. The testing device 1700 may furtherhave a plurality of sample wells 1706, each sample well having one ofthe plurality of immunoassay test pads 1704 disposed within, andallowing for a user to view at least a section of a nitrocellulosemembrane of each of the immunoassay test pads 1704, the membrane 1708having a test line 1708 and control line 1710. The testing device 1700may also have disposed on the surface of the housing a crosshair symbol1712, used as an alignment target. This symbol may be a graphic printedor adhered to the testing device 1700. The crosshair symbol 1712 is usedto align the testing device 1700 for the taking of an image of thetesting device 1700 using a camera on a mobile device, for use in amobile device application described herein. In other embodiments, thecrosshair symbol 1712 may be other types of symbols, such as a simpleshape (circle, square, etc.), other images (such as a medical crosssymbol, an arrow, etc.), or any other type of image. In otherembodiments, the device 1700 may be configured in such a way as to allowa biologic sample to be deposited into a sample well, and to present theresults of the test on the opposite side of the housing. Such aconfiguration would allow the biologic to flow through the testing padwithin the housing, with the reaction occurring on a reactive membraneon the side of the device opposite the sample well, with the devicehaving a window for viewing the results.

Referring now to FIG. 18, there is illustrated a cross-sectional view ofone embodiment of the vertical immunoassay device 1700. There is shownone of the plurality of immunoassay test pads 1704 residing within thehousing 1702 below one of the plurality of sample wells 1706. The one ofthe plurality of immunoassay test pads 1704 includes a immunoreactivemembrane 1802, such as the nitrocellulose membranes disclosed herein.The immunoreactive membrane 1802 may have particle conjugates disposedthereon that binds when a biologic sample is received onto theimmunoreactive membrane 1802 via the sample well 1706, if the biologicsample contains the antigens or antibodies, or other indicators, forwhich the test is configured. The one of the plurality of immunoassaytest pads 1704 also includes an absorbent pad 1804 for collection ofexcess biologic sample. It will be understood that the cross-sectionalview illustrated in FIG. 18 shows one well of the plurality of samplewells 1704. The other wells included in the device 1700 would beconfigured in a similar manner as that shown in FIG. 18. There may alsobe included in the device 1700 an inner separating wall between each ofthe plurality of immunoassay test pads 1704, to ensure that excessbiologic material that is not adequately absorbed by the absorbent pad1804 does not contaminate neighboring immunoassay test pads.

Referring now to FIG. 19, there is illustrated a color gradient chart1900. When the mobile application described herein captures an image ofthe testing device, in some embodiments each pixel that makes up thetest line captured in the image is processed to place it on a colorgradient scale. In some embodiments, this placement may be done byexamining the RGB values of the pixel. For any given test, there may bea visual color indicator (such as a test line) presented to the user ofthe test to indicate whether a reaction occurred. The color that is tobe presented is known for the given test. Additionally, in someembodiments, the strength of the reaction will affect the strength ofthe color indicator. For example, if a test is supposed to produce abrown colored indicator, an image can be taken of the colored indicatorto examine each pixel of the colored indicator to determine the strengthof the color produced on the testing device, which indicates thestrength of the reaction, and thus the risk level for the user.

The embodiment illustrated in FIG. 19 uses as an example a set of pixelRGB results for a test that produces a red colored indicator on the teststrip when a reaction has occurred. There can be seen an origin point1902 on the chart 1900, wherein the RGB value is (255, 255, 255) orwhite. This may represent a no reaction state for the test strip, sincethe test line on the strip may only appear as a white blank space if noreaction has occurred. An x axis 1904 represents the color green,wherein the amount of green in the pixel decreases as it moves away fromthe origin in relation to the x axis 1904. A y axis 1906 represents thecolor blue, wherein the amount of blue in the pixel decreases as itmoves away from the origin in relation to the y axis 1906. A diagonalline 1908 running in between the x axis 1904 and the y axis 1906represents the color red, wherein the diagonal line 1908 running throughthe center of the chart 1900 is a maximum red color all along thediagonal line 1908. If a pixel has less red than a 255 value, the pixelwould be plotted away from the diagonal line 1908 in relation towhichever color is more predominant. For instance, if the pixel has RGBvalues of (127, 50, 205), a shade of purple, the pixel would be plottedsomewhere in the lower right quadrant of the chart 1900. FIG. 19 furtherillustrates an example plurality of pixel plot points 1910, connected bya curved line, wherein the example plurality of pixel plot points 1910shows tests results that likely indicate a positive reaction, as theplot points are all located near the diagonal line 1908, demonstratingthat the colored indicator was a heavy red color for the most part.

Referring now to FIG. 20, there is illustrated a normalized past testsresults chart 2000. The captured pixels may be normalized into a singlevalue for determining whether there is a likelihood of infection,pregnancy, or whatever else the test is designed to detect. This may bedone in various ways. For example, the shade of red in all the pixelsmay be averaged to reach a single RGB value. Outliers may be left out sothat the average is not heavily skewed, especially when there are fewoutliers present. This RGB value may then be given a value, such as arisk rating, ranging from 0 to 100. For example, an RGB value of (255,255, 255) would be given a rating of 0. An RGB value of (255, 0, 0)would be given a rating of 100. An RGB value of (205, 150, 75) may begiven a rating of 70, and so on. This normalized value may then be usedto compare the user of the test to users of past tests to determine arisk level. In some embodiments, the control line and the test line maybe captured and the results compared, as well. In addition, the realresults of risk levels may also be used to adjust the stored normalizedvalue. For instance, if a particular RGB value that seems to indicate astrong reaction repeatedly was found to not indicate an infection, thisvalue may be adjusted to provide a lower risk rating. For instance, if aphysician who saw a patient who had a (205, 150, 75) RGB value laterreported to the operator of the server 1206 that further testing showedno infection was present, and if this trend continued substantially asreported by other physicians or medical organizations, subsequent testresults by other test users that were near the RGB value of (205, 150,75) may be given a lower rating.

Chart 2000 illustrates how past tests results may be collected and usedto determine the risk of a current test user. A y axis 2002 represents arisk level rating, ranging from 0 at the origin to 100. An x axis 2004represents time, wherein a plurality of normalized test results isplotted on the chart 2000. The chart 2000 is further divided intosections across the y axis 2002, indicating various risk levelthresholds. For instance, and as illustrated in the chart 2000, theremay be at certain rating levels different thresholds of risk labeled aslow, moderate, above average, and high risk levels. These thresholds maybe moved over time as more data is accumulated via users conductingtests and the mobile application storing the data on the tests. When auser conducts a test, the user's normalized rating can be plottedsimilarly to past test results and weighed against them in order toprovide a risk level for the user.

Referring now to FIG. 21, there is illustrated the mobile device 802displaying on the screen 804 a mobile application variable testfunctionality. There is displayed on the screen 804 a plurality of testfunctions 2102. The plurality of test functions 2102 may be buttons thatcan be selected by a user to switch between tests within the mobileapplication. This allows for all test functions to be within the samemobile application. For each test run by the mobile application, datafor the particular test chosen is utilized in performing the test,pulling the data from the remote server 1206.

Referring now to FIG. 22, there is illustrated the mobile device 802 ofFIG. 8B, wherein the housing 302 of the testing device 300 also includesthereon test function indicators 2202 and 2204. The test functionindicators 2202 and 2204 are visual markers located on the housing 302that identify to the mobile application the types of tests for which thetesting device 300 is configured. These indicators may be any symbol,alphanumeric character, shape, etc. that can be added to the surface ofthe testing device 300. The mobile application is programmed torecognize the indicator and perform the test function associated withthe indicator. For example, the embodiment illustrated in FIG. 22 showsa “P” symbol for test function indicator 2202 and a “Z” symbol for testfunction indicator 2204. In this embodiment, test function indicator2202 indicates that one test strip in the testing device 300 is apregnancy test, while test function indicator 2204 indicates that onetest strip in the testing device 300 is a Zika test. This is used formerely illustrative purposes, and any recognizable symbol may be usedfor these two test functions, and any other type of test may have asymbol assigned in this way as well. Further, in some embodiments theremay only be one indicator on the housing 302, even if there are multipletests. This single indicator would be for the combined test. Forexample, if the testing device 300 of FIG. 22 had a single symbol of“PZ,” this would indicate that the testing device 300 is a combinedpregnancy and Zika testing device, allowing for the mobile applicationto recognize such and perform each test with knowledge of which strip isassociated with which test based on the stored data on the testingdevice associated with the “PZ” symbol.

Referring now to FIG. 23, there is illustrated the mobile device 802,which in some embodiments is also used to users instructions on how toperform a self-diagnostic test. It is important for users to be able touse diagnostic test products correctly in order to obtain the mostaccurate results and to avoid possible injury to his or herself. Teststhat require a blood sample for the biologic, for example, might requirethe user to prick his finger to obtain the blood. A user could causeinjury to himself if this is not performed correctly. Or, providing thewrong type of biologic, saliva instead of urine, for example, to thesample well 308 or a test strip 100 would likely cause inaccurateresults. For these types of reasons, it is important for the user to beable to perform the test properly. Various regulations also require thatthe users of self-diagnostic tests be sufficiently instructed on theproper use of the tests and testing procedures. In some embodiments,such as is illustrated in FIG. 23, instructions for collectingperforming the diagnostic test are provided by the mobile application invideo and/or audio form. Before collecting the biologic and performingthe diagnostic test, the user launches the mobile application on themobile device 802. The mobile application then provides the user withstep-by-step instructions for the test. In the embodiment illustrated inFIG. 23, a set of video instructions 2302 is presented on the screen804. The video instructions 2302 give detailed guidance on how tocollect the biologic sample or samples and how to put the samples intothe testing device 300, as well as any other steps necessary for thetest. In some embodiments, the mobile application includes controls 2304which allow the user to play, pause, or replay the video instructions2302 or parts of the video instructions. In some embodiments, theinstructions for the diagnostic test are delivered by the mobileapplication on the mobile device 802 in an audio format. In theseembodiments, the mobile application will still show various controls2304 on the screen 804 which allow the user to play, pause, or replaythe audio instructions.

In some embodiments, the file for the video or audio instructions arestored on the mobile device 802, while in other embodiments, the filesare stored on remote servers and then downloaded or streamed to themobile device when the user wishes to view/listen to the instructions.

Turning now to FIG. 24, there is illustrated an embodiment in which amobile device 802 running the mobile application allows users to accesstest instructions by scanning a computer-readable code. In theseembodiments, which allow users to receive instructions via video oraudio formats as described hereinabove with respect to FIG. 23,initiation of the instructions arises from scanning a code with thecamera of the mobile device 802. The mobile application allows for animage of a scan-able product code 2402, which could be a bar code, a QRcode, an alphanumeric code, or any other image than can be decoded bythe application's software, to be captured by a camera on the mobiledevice 802. The scan-able product code 2402 may be found on the exteriorpackaging of the product, on documentation included with the product, oreven on some component of the self-diagnostic test product itself. Thescan-able product code 2402 is linked to the particular type ofself-diagnostic test with which the code was included. This allows theapplication software to determine which set of instructions need to bepresented to the user. Similar to the testing device image capturing andimage processing described hereinabove with respect to FIGS. 8A and 8B,the application displays a graphic 2404 which helps the user align thescan-able product code 2402 in the field of view of the mobile device802 camera so that the camera can capture an acceptable image. When thescan-able product code 2402 aligns with the displayed graphic 2404, themobile application software recognizes this condition and captures animage of the product code. The mobile application then processes theimage of the scan-able product code 2402 and accesses a database to findwhich set of instructions need to be presented to the user. In someembodiments, this database is stored in the software on the mobiledevice 802, while in other embodiments, the database is stored on aremote server and is accessed by the mobile device through the internet.Once the mobile application has determined from the database which setof instructions need to be presented to the user, the applicationretrieves the instruction files from the mobile application or from theremote server and presents the instructions to the user, as describedhereinabove with respect to FIG. 23.

Turning now to FIG. 25, there is illustrated another embodiment in whichinstructions for the diagnostic test are presented in an audio or videoformat by the mobile application. In these embodiments, rather than theuser scanning a product code to inform the mobile application which setof instructions to present as described hereinabove with respect to FIG.24, the user inputs a code into the application. In these embodiments, amenu 2502 is presented on the screen 804 which allows the user to inputan alphanumeric product code 2504 made of a combination of numbersand/or letters which indicate to the mobile application whichinstructions need to be presented. The alphanumeric product code 2504may be printed on the packaging for the test, on documentation includedwith the test, or even on components of the test itself. Once thealphanumeric product code 2504 is input into the mobile application, themobile application accesses the database as described hereinabove withrespect to FIG. 24 to retrieve or access the correct instructions to bepresented to the user.

Turning now to FIG. 26, there is illustrated an embodiment in which themobile application helps ensure that the instructions for theself-diagnostic test have been presented to the user. As discussedhereinabove with respect to FIG. 23, it is important, for variousreasons, for the user of the test to fully understand the proper way toadminister the test. To help ensure that the proper instructions for thetest have been presented to the user, some embodiments include a featurewhich requires the instructions to be fully presented and for the userto acknowledge understanding the instructions. In these embodiments, theinstructions for the diagnostic test are presented by the mobileapplication to the user in the manner described hereinabove with respectto FIGS. 23-25. The video or audio instructions must be presented intheir entirety before the mobile application will allow the user toproceed to the part of the application in which the user captures animage of the testing device 300 to obtain a test result. Once theinstructions have been fully presented to the user, the mobileapplication presents an acknowledgement menu 2602 to the user on thescreen 804 of the mobile device 802. This acknowledgement menu 2602requires the user to acknowledge that he has viewed (or listened) to theinstructions and understands how to administer the self-test. The mobileapplication will not proceed to the step wherein the user captures animage of the testing device for image processing until the useracknowledges viewing (or listening to) and understanding theinstructions. From the acknowledgment menu, the user can either selectthe option 2604 acknowledging he has viewed (or listened to) andunderstands the instructions, sending the application to the test deviceimage capturing steps described hereinabove with respect to FIGS. 23-25,or the user can select the option 2606 which declines to acknowledgeunderstanding the instructions. Selecting that option 2606 will causethe mobile application to re-present the instructions as describedhereinabove with respect to FIG. 23, or cause the mobile applicationproceed to some stage of the application other than the test deviceimage capturing stage.

Turning now to FIG. 27, there is illustrated a flowchart showing theprocess by which instructions are presented to the user via the mobileapplication. The process starts at block 2702, where the user starts themobile application on the mobile device 802. The process then moves todecision block 2704. If the product code provided to the user is not ascan-able product code 2402, then the process moves to block 2706, wherethe user enters an alphanumeric product code 2504 into a menu 2502. Theprocess then moves to block 2716, where the mobile application accessesa database and correlates the alphanumeric product code 2504 to theproper test instructions. If, at decision block 2704, the product codeprovided to the user is a scan-able product code 2402, the processinstead moves to block 2708. Here, the camera on the mobile device 802is activated, and an alignment graphic 2404 appears on the screen 804.Next, the process moves to block 2710, where the scan-able product code2402 is aligned with the graphic on the mobile device screen 804 by theuser. The process then moves to block 2712, where the mobile applicationcauses the mobile device camera to capture an image of the scan-ableproduct code 2402. Next, at block 2414, the mobile application processesthe image of the scan-able product code 2402 and processes it into aformat which will be correlated with the database of instructions. Theprocess then moves to block 2716, where the mobile application on themobile device 802 accesses a database, locally or on a remote server,and correlates the formatted code to the proper instruction set in thedatabase. Next, at block 2718, the mobile application retrieves theproper instruction files, either from the mobile device 802 or from aremote server via the internet. The process then moves to block 2720,where the instructions are presented to the user in either video oraudio format. Next, the process moves to block 2722, where theapplication presents an acknowledgement menu 2602 to the user so thatthe user can acknowledge understanding the instructions. The processmoves to decision block 2724, where, ff the user does not acknowledgeunderstanding the instructions, the process loops back to block 2720,where the instructions are again presented to the user. If the useracknowledges the instructions, the process moves to block 2726, wherethe mobile application allows the user to continue. The process moves toblock 2728, where the user performs the self-diagnostic test, per thegiven instructions. The process then moves to block 2730, where the userscans the testing device 300 for results analysis. The process then endsat End block 2732.

It should be noted that, in some embodiments, the user will be taken toparts of the mobile application other than the playing of theinstructions if the user declines to acknowledge understanding theinstructions. For example, the mobile device 802 could present the userwith a screen that reminds the user that the test cannot proceed untilthe user acknowledges understanding the instructions. The mobileapplication then gives the user another chance to acknowledge theinstructions. Or, in other embodiments, the mobile application returnsthe user to the portion of the application where the user scans orinputs a code to allow the application to retrieve the correctinstruction files.

In some embodiments, when the user acknowledges understanding the testinstructions, a file or data log will be created to document that theuser acknowledged understanding the test instructions. The log willinclude information such as the time at which the instructions wereacknowledged, which diagnostic test the instructions were for, or whichbiologic ID the acknowledgement will be associated with. In someembodiments, the acknowledgement log is stored on the mobile device 802in the mobile application software, while in other embodiments, theacknowledgement log is transmitted to a remote server for storage andrecord-keeping.

Turning now to FIG. 28, there is illustrated a flowchart for embodimentsin which the image of the testing device 300 is processed by a databaseon a remote server, rather than by the mobile application itself runningon the mobile device 802. These embodiments are useful for when a mobileapplication is capable of working with multiple different tests suchthat storing information and data needed to process several differenttypes of tests might consume more data storage on a single mobile devicethan is practical or desirable. The process starts at Start block 2802,after the user has deposited the biologic sample into the testing device300 and any chemical reactions have occurred. The process then moves toblock 2804, where the mobile application activates the camera on themobile device 802. The process moves to block 2806, where the user usesthe mobile application to capture an image of the testing device 300with the mobile device 802 camera. Next, at block 2808, the mobileapplication communicates over the internet the image of the testingdevice 300, along with information identifying the type of test beingconducted, to a remote server and database for analysis. At block 2810,the database analyzes the received test information and image andgenerates test results. This step is analogous to the steps describedhereinabove with respect to FIGS. 9, 11 and 14, except that the imageanalysis takes place on a remote server and database, rather than on themobile device itself. The process then moves to block 2812, where theserver communicates the test results back to the mobile applicationrunning on the mobile device 802. The process then ends at block 2814.

Turning now to FIG. 29, there is illustrated a mobile device 802 from anembodiment which includes delivering audiovisual messages to aself-diagnostic test user in response to the user performing the testand submitting the test for results. After a biologic sample 204 isplaced within the testing device 300, a certain amount of time isrequired for the sample to migrate into the various parts of the stripor strips 204, for any chemical reaction to occur, and for any visualindicators to appear in the testing device 300. During this time, theuser is somewhat of a “captive audience,” in that he will likely befocused on the test and the mobile application, rather than otheraspects of daily life, while he is waiting for the test to be completed.This means that content providers of audiovisual messages know thattheir content is more likely to be paid attention to by the mobileapplication user. This, in turn, means that content presented to userscan demand a premium price. Some embodiments of the system, such as thatillustrated in FIG. 29, take advantage of the user being a “captiveaudience” and allow the mobile application to present targetedaudiovisual messages 2902 to the user. This occurs during the timebetween the user placing the biologic sample 204 in the testing device300 and the time when the testing device is ready to have its imagecaptured by the camera for analysis by the mobile application or remoteserver. In some embodiments, the targeted audiovisual messages 2902 arein the form a “TV channel” which provides health-related content andprogramming. This programming can include long-format video messages2902 that are approximately thirty minutes in length such as might befound on a traditional TV channel and can resemble television shows orinfo-mercials. The programming can also include audiovisual messages2902 in the form of shorter video segments that are anywhere between oneminute and five minutes in length. Some embodiments will present thesame audiovisual messages 2902 to all users, regardless of whichdiagnostic test the user is performing. In other embodiments, thespecific audiovisual messages 2902 presented to a particular user willdepend on which diagnostic test the user is using. For example, if auser is performing a pregnancy test, the audiovisual messages 2902 willbe related to babies or pregnancy. If a user is performing an HIV test,the audiovisual messages 2902 delivered to the user will be related toHIV treatment and management. Audiovisual messages 2902 can be createdthat relate to any of the types of tests found in various embodiments ofthe system.

Some embodiments will also include a countdown clock 2904. The countdownclock 2904 is presented on the mobile device screen 804 while thebiologic is moving through the test device 300 and any chemicalreactions are occurring, which is also when audiovisual messages 2904are being presented to the user. The countdown clock 2904 displays thetime until the test device 300 is ready to be photographed by the camerafor processing by the mobile application or remote server. The inclusionof a countdown clock 2904 is another tool which helps keep the userfocused on the mobile application while the audiovisual messages 2902are being presented. In some embodiments, a countdown clock 2904 ispresented to the user after any reactions have occurred and an image ofthe test device 300 has been captured by the camera. In theseembodiments, the countdown clock 2904 displays the time left until thetest device image is processed by the mobile application or the remoteserver and a result is delivered and presented to the user. Thecountdown clock 2904 is started by the user indicating through a menuthat he has placed a biologic sample in the testing device 300. Itshould be noted that the countdown clock 2904 is related to the timeleft for the reaction to complete (or the test device image to beprocessed), but in some embodiments, additional time is added to thecountdown clock beyond just the completion time of the reaction or theimage processing. In these embodiments, the countdown clock 2904 beginswhen the user photographs the testing device 300 for results analysis.Different types of self-diagnostic tests will have different testcompletion times. These times are stored in a database in the mobileapplication, or, in some embodiments, on a remote server whichcommunicates the testing times to the mobile application.

In some embodiments, the audiovisual messages 2902 are presented to theuser after the mobile device 802 camera has captured an image of thetest device 300 for processing by the mobile application or the remoteserver and database. In these embodiments, the audiovisual messages 2902that are presented after the user captures a test device 300 image arein addition to audiovisual messages presented while the user is waitingfor any chemical reactions to take place in the test device before theimage is captured. In still other embodiments, audiovisual messages 2902are presented only after the image of the test device 300 is capturedand is being processed by the mobile application or the remote serverand database.

Turning now to FIG. 30, there is illustrated a flowchart for the processof streaming audiovisual messages 2902 to a mobile application on amobile device 802. In some embodiments, the audiovisual messages 2902are stored on the mobile device 802 itself. Preferably, however, theaudiovisual messages 2902 are stored on a remote message database andthen streamed by a server to the mobile device 802 which is running themobile application. The process starts at block 3002 and proceeds toblock 3004, where the mobile application communicates information aboutthe diagnostic test to the remote servers. This information notifies theserver and database that the user is performing a diagnostic test andthat the mobile application is ready to stream audiovisual messages 2902to the user. For embodiments in which the audiovisual messages 2902 thatare presented to the user are specific to the type of diagnostic testthe user is performing, this information also includes informationidentifying the specific type of self-diagnostic test. Next, the processmoves to block 3006, where the testing time is determined from thediagnostic test identification information. In some embodiments, thetesting time is communicated to the mobile application from a remoteserver, while in other embodiments, this time is stored in a databasewithin the mobile application. Next, at block 3006, an appropriateaudiovisual message 2902 or set of messages is selected from a messagedatabase. For embodiments which present specific messages 2902 to usersof specific diagnostic tests, the test-identifying information is usedby the database to select a message related to the type of test beingused. The process then moves to block 3008, where the remote serverstreams the audiovisual messages 2902 to the mobile device 802 runningthe mobile application. Next, at block 3010, the mobile applicationpresents the audiovisual messages 2902 to the user. The process ends atblock 3012.

It should be understood that the drawings and detailed descriptionherein are to be regarded in an illustrative rather than a restrictivemanner, and are not intended to be limiting to the particular forms andexamples disclosed. On the contrary, included are any furthermodifications, changes, rearrangements, substitutions, alternatives,design choices, and embodiments apparent to those of ordinary skill inthe art, without departing from the spirit and scope hereof, as definedby the following claims. Thus, it is intended that the following claimsbe interpreted to embrace all such further modifications, changes,rearrangements, substitutions, alternatives, design choices, andembodiments.

What is claimed is:
 1. A method of a mobile device for providing atelevision network in response to an input, the method comprising:capturing an image of a medical testing device; transmitting diagnostictest information to a remote server and a database; and receiving, inresponse to the transmission of the diagnostic test information, astream of audiovisual messages from the remote server, wherein thestream of audiovisual messages includes image or video contentpertaining to information regarding use of the medical testing device orone or more medical conditions corresponding to a type of test of themedical testing device, and wherein the stream of audiovisual messagesis received for a determined amount of time based on the type of test ofthe medical testing device.
 2. The method of claim 1, further comprisingpresenting the audiovisual messages on a viewing screen of the mobiledevice.
 3. The method of claim 1, further comprising: presenting a testresult on a viewing screen of the mobile device.
 4. The method of claim1, further comprising presenting on a viewing screen of the mobiledevice a menu which provides an option to acknowledge an audiovisualmessage.
 5. The method of claim 1, further comprising: transmitting theimage of the medical testing device to the remote server; and receivinga test result from the remote server.
 6. The method of claim 5, furthercomprising: providing a risk indicator alerting a user to seek medicalattention immediately.
 7. A system for providing a television network inresponse to an input, the system comprising: a medical testing devicehaving thereon an alignment target and having a plurality of immunoassaytest strips, the plurality of immunoassay test strips each including: asample pad capable of receiving a biologic sample; a conjugate padcontaining particles for conjugating with antibodies or antigens presentin the biologic sample; and a membrane strip having a test line and acontrol line, wherein the test line and the control line are viewable;and a mobile device having a camera, a viewing screen, and a softwareapplication stored thereon, wherein the software application providesexecutable instructions to: capture an image of the medical testingdevice; transmit diagnostic information to a remote server and adatabase; and receive, in response to the transmission of the diagnosticinformation, a stream of audiovisual messages from the remote server,wherein the stream of audiovisual messages includes image or videocontent pertaining to information regarding use of the medical testingdevice or one or more medical conditions corresponding to a type of testof the medical testing device, and wherein the stream of audiovisualmessages is received for a determined amount of time based on the typeof test of the medical testing device.
 8. The system of claim 7, whereinthe software application further provides executable instructions to:present the audiovisual messages on the viewing screen of the mobiledevice.
 9. The system of claim 7, wherein the software applicationfurther provides executable instructions to: present a test result onthe viewing screen of the mobile device.
 10. The system of claim 7,wherein the software application further provides executableinstructions to: present on the viewing screen of the mobile device amenu which provides an option to acknowledge an audiovisual message. 11.The system of claim 7, wherein the software application further providesexecutable instructions to: transmit the image of the medical testingdevice to the remote server; and receive a test result from the remoteserver.
 12. The system of claim 11, wherein the software applicationfurther provides executable instructions to: provide a risk indicatoralerting a user to seek medical attention immediately.
 13. A method of aserver for providing a television network in response to an input, themethod comprising: receiving, from a mobile device, diagnostic testinformation corresponding to a medical testing device; selecting, inresponse to receiving the diagnostic test information, and based on atype of test of the medical testing device, audiovisual messages from amessage database, wherein the audiovisual messages include image orvideo content pertaining to information regarding use of the medicaltesting device or one or more medical conditions corresponding to thetype of test of the medical testing device; and streaming the selectedaudiovisual messages to the mobile device for a determined amount oftime based on the type of test of the medical testing device.
 14. Themethod of claim 13, further comprising transmitting a diagnostic testresult to the mobile device.